EFFECT OF 3 WEEKS TREATMENT WITH YOHIMBINE ON SALIVARY SECRETION IN HEALTHY-VOLUNTEERS AND IN DEPRESSED-PATIENTS TREATED WITH TRICYCLIC ANTIDEPRESSANTS

被引:12
作者
BAGHERI, H
SCHMITT, L
BERLAN, M
MONTASTRUC, JL
机构
[1] CHU TOULOUSE,FAC MED,PHARMACOL MED & CLIN LAB,INSERM,U317,37 ALLEES JULES GUESDE,F-31073 TOULOUSE,FRANCE
[2] CHU PURPAN,SERV HOSP UNIV PSYCHIAT,F-31059 TOULOUSE,FRANCE
关键词
YOHIMBINE; SALIVARY SECRETION; TRICYCLIC ANTIDEPRESSANTS; ALPHA-2-ADRENOCEPTORS; ALPHA-2-ADRENOCEPTOR ANTAGONISTS;
D O I
10.1111/j.1365-2125.1992.tb05661.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of yohimbine treatment (4 mg three times daily) for 3 weeks on salivary secretion was investigated. In healthy volunteers, acute administration of yohimbine increased salivary volume within 1 h to a similar extent before and at the end of the treatment period. In depressed patients treated with tricyclic antidepressants (and exhibiting a reduced salivary flow), yohimbine also acutely increased salivary volume. In contrast, the alpha2-adrenoceptor antagonist failed to modify resting values measured in the morning (i.e. 10 and 14 h after the last administration in healthy volunteers and depressed patients respectively). This result indicates that alpha2-adrenoceptor antagonists may have a potential therapeutic use in the treatment of dry mouth caused by tricyclic antidepressant drugs.
引用
收藏
页码:555 / 558
页数:4
相关论文
共 12 条
[1]   IS YOHIMBINE-INDUCED INCREASE IN SALIVARY SECRETION A KININ-DEPENDENT MECHANISM [J].
BAGHERI, H ;
BOMPART, G ;
GIROLAMI, JP ;
MONTASTRUC, JL ;
MONTASTRUC, P .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1992, 6 (01) :17-20
[2]  
BLACKWELL B, 1978, AM J PSYCHIAT, V135, P722
[3]   YOHIMBINE INCREASES HUMAN SALIVARY SECRETION [J].
CHATELUT, E ;
RISPAIL, Y ;
BERLAN, M ;
MONTASTRUC, JL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 28 (03) :366-368
[4]  
GALITZKY J, 1990, EUR J CLIN PHARMACOL, V39, P447
[5]   YOHIMBINE INCREASES SUBMAXILLARY KALLIKREIN RELEASE INTO THE SALIVA IN DOGS - EVIDENCE FOR ALPHA-2-ADRENOCEPTOR-MEDIATED INHIBITION OF CHOLINERGIC PATHWAYS [J].
GIROLAMI, JP ;
BASCANDS, JL ;
PECHER, C ;
BERLAN, M ;
MONTASTRUC, JL ;
MONTASTRUC, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 102 (02) :351-354
[6]  
GOLDBERG MR, 1983, PHARMACOL REV, V35, P143
[7]   YOHIMBINE BIOAVAILABILITY IN HUMANS [J].
GUTHRIE, SK ;
HARIHARAN, M ;
GRUNHAUS, LJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (04) :409-411
[8]   EFFECT OF YOHIMBINE ON BLOOD-PRESSURE IN PATIENTS WITH DEPRESSION AND ORTHOSTATIC HYPOTENSION INDUCED BY CLOMIPRAMINE [J].
LACOMBLEZ, L ;
BENSIMON, G ;
ISNARD, F ;
DIQUET, B ;
LECRUBIER, Y ;
PUECH, AJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (03) :241-251
[9]   DETERMINATION OF YOHIMBINE AND ITS 2 HYDROXYLATED METABOLITES IN HUMANS BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND MASS-SPECTRAL ANALYSIS [J].
LEVERGE, R ;
LECORRE, P ;
CHEVANNE, F ;
DEMAINDREVILLE, MD ;
ROYER, D ;
LEVY, J .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 574 (02) :283-292
[10]   EFFECTS OF YOHIMBINE ON SUBMAXILLARY SALIVATION IN DOGS [J].
MONTASTRUC, P ;
BERLAN, M ;
MONTASTRUC, JL .
BRITISH JOURNAL OF PHARMACOLOGY, 1989, 98 (01) :101-104